sellModerate cluster of 510b5-1 plan
Baynes Roy D. sold $5.4M of NTRA
director at Natera, Inc.. 37,230 shares at an average of $146.11, traded Nov 15, 2024, filed Nov 15, 2024.
Warning score
40Value
$5.4M
37,230 shares
Holdings after
15,807
-70% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-027020, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | MOption exercise Common Stock10b5-1 | +22,000 | $22.83 | $502k | 37,807 | Nov 15, 2024 |
| Nov 15, 2024 | MOption exercise Common Stock10b5-1 | +15,230 | $24.42 | $372k | 53,037 | Nov 15, 2024 |
| Nov 15, 2024 | SOpen-market sale Common Stock10b5-1 | -5,500 | $144.26 | $793k | 47,537 | Nov 15, 2024 |
| Nov 15, 2024 | SOpen-market sale Common Stock10b5-1 | -16,404 | $145.21 | $2.4M | 31,133 | Nov 15, 2024 |
| Nov 15, 2024 | SOpen-market sale Common Stock10b5-1 | -1,770 | $146.26 | $259k | 29,363 | Nov 15, 2024 |
| Nov 15, 2024 | SOpen-market sale Common Stock10b5-1 | -9,467 | $147.31 | $1.4M | 19,896 | Nov 15, 2024 |
| Nov 15, 2024 | SOpen-market sale Common Stock10b5-1 | -2,106 | $148.74 | $313k | 17,790 | Nov 15, 2024 |
| Nov 15, 2024 | SOpen-market sale Common Stock10b5-1 | -1,983 | $149.98 | $297k | 15,807 | Nov 15, 2024 |
| Nov 15, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -22,000 | $0.00 | $0 | 0 | Nov 15, 2024 |
| Nov 15, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -15,230 | $0.00 | $0 | 0 | Nov 15, 2024 |
Related signals
Other insiders at Natera, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 25Weak | sell 510b5-1 | NTRA Natera, Inc. | Fesko John PRESIDENT, CHIEF BUS. OFFICER | $107k | 669 | |
| 31Weak | sell 510b5-1 | NTRA Natera, Inc. | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | $388k | 2,428 | |
| 34Weak | sell 510b5-1 | NTRA Natera, Inc. | Sheena Jonathan director, other | $953k | 5,700 | |
| 40Moderate | sell 610b5-1 | NTRA Natera, Inc. | Rabinowitz Matthew EXECUTIVE CHAIRMAN | $27M | 160,000 | |
| 49Moderate | sell 6 | NTRA Natera, Inc. | Chapman Rowan E director | $301k | 1,767 | |
| 22Weak | sell 610b5-1 | NTRA Natera, Inc. | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | $809k | 4,858 | |
| 55Moderate | sell 5 | NTRA Natera, Inc. | BOTHA ROELOF director | $15M | 87,473 | |
| 35Weak | sell 710b5-1 | NTRA Natera, Inc. | Rabinowitz Matthew EXECUTIVE CHAIRMAN | $665k | 4,000 | |
| 65Notable | sell 6 | NTRA Natera, Inc. | Marcus Gail Boxer director | $1.5M | 9,682 | |
| 41Moderate | sell 510b5-1 | NTRA Natera, Inc. | Chapman Steven Leonard CEO AND PRESIDENT | $692k | 4,728 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.